Consilium Medicum (Aug 2023)

Non-alcoholic fatty liver disease: from understanding risk factors to finding optimal treatment regimens: A review

  • Daria A. Teplyuk,
  • Aliya A. Kaisina,
  • Shabnam I. Ibragimova,
  • Afina A. Bestavashvili,
  • Irina O. Tinkova,
  • Evgeniia Iu. Pashkova,
  • Jamilya A. Kaibullayeva,
  • Alexander V. Nersesov,
  • Chavdar S. Pavlov

DOI
https://doi.org/10.26442/20751753.2023.5.202272
Journal volume & issue
Vol. 25, no. 5
pp. 325 – 332

Abstract

Read online

Non-alcoholic fatty liver disease (NAFLD) is now a major risk factor for death among patients with liver disease. Currently, drugs that primarily affect surrogate markers of NAFLD are available. However, none of these drugs showed a significant effect on the course of steatohepatitis and fibrogenesis. The search for the most relevant lifestyle modification programs is still a priority in comprehensive treatment. A clinical case of follow-up of a comorbid patient is presented. Despite comprehensive treatment, disease regression was not achieved. NAFLD therapy remains a relevant issue. Finding new ways to affect the NAFLD course and individualize treatment approaches is necessary.

Keywords